2018 ADC Symposium
Save the date!
Tuesday, October 30, 2018
You are invited to participate in Merck’s 2018 ADC Symposium to learn, share and discuss today’s advancements with your peers and subject matter experts of the industry.
This one-day event will include:
|9:45 AM||Registration & Morning Coffee|
|10:20 AM||Welcome & Introduction|
| ||Robert Guagliardo, VP & Head of Actives & Formulation Commercial, Merck|
| ||Advancing Development of ADCs & Bioconjugation|
|10:30 AM||Hydrophilic and Site-Specific Antibody- Drug Conjugates to Treat Tumors|
| ||Dr. Ping-Fu Cheng, ITRI (Taiwan)|
|11:00 AM||ABL201: an anti-BCMA antibody-drug conjugate with NTERM conjugation|
| ||Dr. Jinwon Jung, ABL Bio Inc.|
|11:45 AM||Creating Next Generation ADCs with Industry Leading DAR Precision and Plasma Stability|
| ||Dr. Jeiwook Chae, LegoChem Biosciences Inc.|
|12:15 PM||ADCs with high DAR, high targeting valence, and product homogeneity|
| ||Dr. Tse Wen Chang, Immunwork Inc.|
|12:45 PM||Lunch Break|
| ||Technology Insights & Processing Solutions|
|1:30 PM||Evaluation of a Novel Single-use TFF Capsule|
| ||Yoshiaki Ogawa, Merck|
|1:45 PM||Single use Equipment for ADC Processing: From Lab Sale to GMP Production|
| ||Siyi Liao, Merck|
Dr. Gang Yao, Merck
|2:15 PM||Demonstration of Solvent Compatibility and Extractables Profile for Use of Mobius® Assemblies in ADC Processing|
| ||Dr. Takao Ito, Merck|
|2:30 PM||MLab™ Collaboration Center rotating group tours, Q&A time with experts, poster exhibition & coffee break|
|3:45 PM||Trends in Drug-linker Technologies: novel HPAPIs, Discrete & Activated PEGs|
| ||Dr. Matthias Joehnck, Merck|
|4:15 PM||Tackling the Complex ADC Supply Chain: Best Practice Approach and Integrated Program Management Case Study|
| ||Latashuia Browning, Merck|
|4:45 PM||Wrap-up and closing remarks|
| ||Isao Hatano, Head of Process Solutions Japan, Merck|
|5:00 PM||Post-event reception|
| ||Grand Nikko Daiba, 29F (Akane), 2-6-1, Daiba, Minato-ku, Tokyo 135-8701, Japan|
The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the US and Canada.
* This agenda is subject to change and will be updated during the course of the next months. The event is free; registration is mandatory and space is limited to 40 attendees. Attendance to the “2018 ADC Symposium” is limited and available to pharma/biopharma manufacturers only. The offer does not extend to any company that provides products or services to the pharma/biopharma industry. Merck reserves the right to revoke or refuse participation at any times.
Refreshments are provided courtesy of Merck. Travel costs, hotel accommodations and any other costs incurred are at the expense of the attendees.
Hydrophilic and Site-Specific Antibody- Drug Conjugates to Treat Tumors
Cheng PingFu, Ph.D.
Principal Investigator of site-specific ADC project
ABL201: an Anti-BCMA Antibody-drug Conjugate with NTERM Conjugation
Jinwon Jung, Ph.D.
Principal Scientist, ABL Bio Inc.
Creating Next Generation ADCs with Industry Leading DAR Precision and Plasma Stability
Jeiwook Chae, Ph.D.
Chief Business Development Officer, LegoChem Biosciences, Inc.
ADCs with high DAR, high targeting valence, and product homogeneity
Tse-Wen Chang, Ph.D.
CEO, Immunwork, Inc.
Evaluation of a Novel Single-use TFF Capsule
Technology Manager for Tangential Flow Filtration (TFF), Merck
Implementation of a Complete Single-use Production Process & Scale-up Case Study
Gang Yao, Ph.D.
Principal Scientist, Process and Analytical Development, Merck
Mobius® Technology Supporting ADC Processing
System Process Engineer, Manufacturing Sciences And Technology,
Demonstration of Solvent Compatibility and Extractables Profile for Use of Mobius® Assemblies in ADC Processing
Takao Ito, Ph.D.
Head of Manufacturing Sciences & Technology (MSAT) Japan and Korea, Merck
Trends in Drug-linker Technologies: HPAPIs & activated PEGs
Matthias Jöhnck, Ph.D.
Senior Director, Head of Actives & Formulation, Research & Development, Merck
Tackling the Complex ADC Supply Chain: Best Practice Approach and Integrated Program Management Case Study
Sr. Director & Head of Sales, Americas, Actives & Formulation, Merck